Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TechCrunch
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Continue reading on the source website
To respect copyrights, we only provide a brief summary. Read the full article on TechCrunch.
Read Full Article